{"id":2338,"date":"2025-04-04T13:35:00","date_gmt":"2025-04-04T13:35:00","guid":{"rendered":"https:\/\/ipfray.com\/?p=2338"},"modified":"2025-04-21T08:34:37","modified_gmt":"2025-04-21T08:34:37","slug":"gsk-and-pfizer-settle-global-rsv-vaccine-patent-dispute","status":"publish","type":"post","link":"https:\/\/ipfray.com\/staging1\/gsk-and-pfizer-settle-global-rsv-vaccine-patent-dispute\/","title":{"rendered":"GSK and Pfizer settle global RSV vaccine patent dispute"},"content":{"rendered":"\n
\n

Context: <\/strong>In August 2023, GlaxoSmithKline (GSK) initiated patent infringement actions against Pfizer in both the District of Delaware and the Unified Patent Court (UPC) (ip fray<\/strong> LinkedIn post<\/a>), alleging that the defendant\u2019s respiratory syncytial virus (RSV) vaccine infringed several of GSK\u2019s patents related to antigen technology. Pfizer denied the allegations and argued that GSK’s patents were invalid. GSK\u2019s RSV vaccination, also known as Arexvy, is responsible for two-thirds of U.S. RSV shot sales (May 2024, GSK press release<\/a>). The vaccine helps treat a condition that typically causes cold-like symptoms but can also lead to pneumonia in toddlers and older adults. In a decision last October, and a huge win for Pfizer, the UK High Court invalidated two of GSK\u2019s RSV-related patents, EP3109258<\/a> and EP2222710<\/a>.<\/p>\n\n\n\n

What’s new:<\/strong> GSK and Pfizer have settled their dispute, according to a filing in the District of Delaware. The companies stated in the filing that they would dismiss the case with prejudice, which means it cannot be refiled.<\/p>\n\n\n\n

Direct impact and wider ramifications:<\/strong> This filing also brings an end to the parties\u2019 pending litigation in the UPC. However, GSK and Pfizer\u2019s patent infringement dispute over the latter\u2019s COVID-19 vaccine, Comirnaty, is still pending.<\/p>\n<\/div>\n\n\n\n

This is the stipulation of dismissal:<\/p>\n\n\n\n